CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia-inducible factor (HIF), today
announced that it will host an Analyst and Investor Day on Tuesday, June
27, 2017. The event is scheduled to take place from 8:00-11:00 AM
Eastern Time in New York City.
The agenda will include a review of the Company's HIF programs as well
as presentations by the following guest speakers:
Geoffrey A. Block, M.D., Director of Research, Denver Nephrology
Cormac Taylor B.Sc., Ph.D., Professor of Cellular Physiology,
University College Dublin, School of Medicine
A live audio webcast of the event will be available on the Company's
website at http://ir.akebia.com/events.cfm.
To ensure a timely connection, users should register at least 15 minutes
prior to the scheduled start. An archived replay will be available for
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through hypoxia-inducible factor
biology. Akebia's lead product candidate, vadadustat, is an oral,
investigational therapy in development for the treatment of anemia
related to chronic kidney disease in both non-dialysis and dialysis
patients. Akebia's global Phase 3 program for vadadustat, which includes
the PRO2TECT studies for non-dialysis patients with anemia
secondary to chronic kidney disease and the INNO2VATE studies
for dialysis-dependent patients, is currently ongoing. For more
information, please visit our website at www.akebia.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170620005296/en/
Theresa McNeely, 617-844-6113
and Investor Relations
Source: Akebia Therapeutics, Inc.
News Provided by Acquire Media